Recently, a Phase IIb trial of newly diagnosed patients with stage III/IV ovarian cancer demonstrated greater clinical benefit involving significant advantages in RFS and OS in patients with BRCA1/2 wild-type ovarian cancer [19]. This evidence concerns the gene BRCA1 and ovarian carcinoma.